Adherium Investor Conference Call


SAN MATEO, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, will host a conference call on Wednesday, February 7, 2018 at 6:00pm EDT/Thursday, February 8, 2018 at 10:00am AEDT to discuss its Half Year Results to December 31, 2017.

Arik Anderson, Chief Executive Officer will host the call and will be joined by Adherium’s VP Finance and Business Services, Rob Turnbull, and Adherium’s Founder, Garth Sutherland.

Conference Call details:

Conference ID: 6589038

Dial-in Details:
Australia: 1800 123 296 or +61 2 8038 5221
New Zealand: 0800 452 782
Hong Kong: 800 908 865
United States: 1 855 293 1544

Webcast:  http://www.openbriefing.com/OB/2812.aspx

For overseas participants, the conference call will commence at:

     
- 12:00pm on Thursday, February 8, 2018 (New Zealand Daylight Time)
- 7:00am on Thursday, February 8, 2018  (Hong Kong Time)
- 3:00pm on Wednesday, February 7, 2018 (U.S. Pacific Daylight Time)
- 6:00pm on Wednesday, February 7, 2018 (U.S. Eastern Daylight Time)
     

A recording of the call will be made available in the ‘Investor Centre’ section of the Company website at http://adherium.com/investors/ and at http://www.openbriefing.com/

About Adherium
Adherium is a provider of digital health solutions. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of "smart" medication sensors for respiratory medications to address sub-optimal medication use and improve health outcomes in chronic disease.  Adherium is headquartered in the USA, and operates globally from bases in the USA, Europe and Australasia.

Inquiries

United States:
Vik Panda, VikP@adherium.com
Leigh Salvo, Gilmartin Group, leigh@gilmartinir.com, +1 415 937 5404

Europe:              
Scott Fleming, ScottF@adherium.com, +31 6 4687 6989

Australia:          
Michael Brown, Pegasus Corporate Advisory, +61 400 248 080

Email:                 
investors@adherium.com

Web:                   
www.adherium.com